Medtronic plc (MDT) has shared late-breaking clinical trial results for its PulseSelect Pulsed Field Ablation (“PFA”) system, demonstrating a high rate of durable lesion formation in treating atrial fibrillation (Afib). The findings were presented at the Asia Pacific Heart Rhythm Society meeting held in Sydney, Australia.The widespread adoption of PulseSelect also continues, with more than 10,000 cases having been performed worldwide.Predicting MDT Stock Movement Following the NewsAfter the announcement, Me ...